Sylentis Announces New Data on the Treatment of Allergic Conjunctivitis

At the ARVO meeting, Sylentis presented preclinical results on its RNAi therapy, demonstrating how SYL116011 acts on seasonal ocular allergies

SYL116011, which is being researched for ocular allergies caused by pollen, reduces the symptoms related to allergy, such as swelling and tearing, by 50% to 80%, according to Sylentis. SYL116011 is administered once a day and has fewer secondary effects than antihistamines that can provoke itchy eyes and drowsiness, and is typically administered 3-4 times a day.

“Eye allergies are one of the most common illnesses that allergists and ophthalmologists come across. The problem is that a majority of the drugs that are available for the treatment of ocular allergies are focused on alleviating, from time to time, the symptoms,” Ana Isabel Jiménez, Director of R&D at Sylentis, said in a company news release.